Abstract
Estrogens have been recently postulated as potential agents in the development and progression of prostate cancer. Previous studies have demonstrated presence of both variants of estrogen receptor (ER); ER alpha (ERα) and ER beta (ERβ) in differing proportions between normal prostate and prostate cancer. It has been previously suggested that estrogens may either accelerate or inhibit growth of prostate cancer cell growth, depending on ER status. In particular, ERβ is considered to have a growth inhibitory role in prostate tissue. ERβ is significantly expressed in human prostate cancer cells, and hence it is considered a key factor for anti-cancer therapy. Therefore, various types of ERβ ligands have been investigated to clarify the mechanism of ERβ-mediated pathway of inhibitory effects on prostate cancer cells. Herein, we review recent examinations of ERs in prostate cancer, and the significance of ER mediated signaling pathways, with a focus on ERβ, as prospective therapeutic targets in prostate cancer.
Keywords: Estrogen receptor alpha(ERα), estrogen receptor beta (ERβ), GRP30, prostate cancer, steroid metabolism
Current Molecular Pharmacology
Title:Estrogen Receptor Expression and its Relevant Signaling Pathway in Prostate Cancer: A Target of Therapy
Volume: 5
Author(s): Yasuhiro Nakamura, Keely M McNamara and Hironobu Sasano
Affiliation:
Keywords: Estrogen receptor alpha(ERα), estrogen receptor beta (ERβ), GRP30, prostate cancer, steroid metabolism
Abstract: Estrogens have been recently postulated as potential agents in the development and progression of prostate cancer. Previous studies have demonstrated presence of both variants of estrogen receptor (ER); ER alpha (ERα) and ER beta (ERβ) in differing proportions between normal prostate and prostate cancer. It has been previously suggested that estrogens may either accelerate or inhibit growth of prostate cancer cell growth, depending on ER status. In particular, ERβ is considered to have a growth inhibitory role in prostate tissue. ERβ is significantly expressed in human prostate cancer cells, and hence it is considered a key factor for anti-cancer therapy. Therefore, various types of ERβ ligands have been investigated to clarify the mechanism of ERβ-mediated pathway of inhibitory effects on prostate cancer cells. Herein, we review recent examinations of ERs in prostate cancer, and the significance of ER mediated signaling pathways, with a focus on ERβ, as prospective therapeutic targets in prostate cancer.
Export Options
About this article
Cite this article as:
Nakamura Yasuhiro, M McNamara Keely and Sasano Hironobu, Estrogen Receptor Expression and its Relevant Signaling Pathway in Prostate Cancer: A Target of Therapy, Current Molecular Pharmacology 2012; 5 (3) . https://dx.doi.org/10.2174/1874467211205030008
DOI https://dx.doi.org/10.2174/1874467211205030008 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Editorial Board Member
Current Chemical Biology Regulation of Tumor Angiogenesis by the Immune System
Current Angiogenesis (Discontinued) The Need for Calcium Channels in Cell Proliferation
Recent Patents on Anti-Cancer Drug Discovery Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Liposomal Targeting of Angiogenic Vasculature
Current Drug Delivery Nanotechnological Strategies to Improve Water Solubility of Commercially Available Drugs
Current Nanomedicine Induction of Thyroid Neoplasm Following Plant Medicine Marine Algae (Sargassum): A Rare Case and Review of the Literature
Current Pharmaceutical Biotechnology Recent Advances in Antiangiogenic Agents with VEGFR as Target
Mini-Reviews in Medicinal Chemistry The Immunomodulatory Potential of Selected Bioactive Plant-Based Compounds in Breast Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Glucose-6-phosphate Dehydrogenase: a Biomarker and Potential Therapeutic Target for Cancer
Anti-Cancer Agents in Medicinal Chemistry Cardiovascular Effects of EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibodies
Cardiovascular & Hematological Agents in Medicinal Chemistry Research and Development in Betulin and Betulinic Acid Derived Triterpenoids
Mini-Reviews in Organic Chemistry Role of Calcium, Vitamin D, and the Extrarenal Vitamin D Hydroxylases in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry The Role of Non-coding Genome in Cancer-associated Fibroblasts; Stateof- the-Art and Perspectives in Cancer Targeted Therapy
Current Drug Targets The Accomplices of NF-κB Lead to Radioresistance
Current Protein & Peptide Science Mitochondria, Cellular Stress Resistance, Somatic Cell Depletion and Lifespan
Current Aging Science Epigenetic Effects of Cadmium in Cancer: Focus on Melanoma
Current Genomics The ATP-driven Hsp60 Machinery: Biological and Clinical Implications
Current Immunology Reviews (Discontinued) The Recombinant T Cell Receptor Strategy: Insights into Structure and Function of Recombinant Immunoreceptors on the Way Towards an Optimal Receptor Design for Cellular Immunotherapy
Current Gene Therapy Modulation of intracellular pH in human ovarian cancer.
Current Molecular Medicine